Dynavax Technologies Corporation (0IDA.L)
USD 12.75
(-1.43%)
USD 12.75
(-1.43%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 106.63 Million USD | 90.4% |
| 2022 | 56 Million USD | 131.32% |
| 2021 | -178.8 Million USD | -196.25% |
| 2020 | 185.77 Million USD | 5.22% |
| 2019 | 176.56 Million USD | 242.69% |
| 2018 | 51.52 Million USD | 293.81% |
| 2017 | -26.58 Million USD | -9.45% |
| 2016 | -24.28 Million USD | 45.8% |
| 2015 | -44.81 Million USD | -12.16% |
| 2014 | -39.95 Million USD | -72.79% |
| 2013 | -23.12 Million USD | -204.28% |
| 2012 | -7.59 Million USD | 60.28% |
| 2011 | -19.13 Million USD | -79.28% |
| 2010 | -10.67 Million USD | 61.02% |
| 2009 | -27.37 Million USD | 2.58% |
| 2008 | -28.1 Million USD | -96.62% |
| 2007 | -14.29 Million USD | -0.98% |
| 2006 | -14.15 Million USD | -62.22% |
| 2005 | -8.72 Million USD | 47.41% |
| 2004 | -16.59 Million USD | 29.31% |
| 2003 | -23.46 Million USD | -353.84% |
| 2002 | -5.17 Million USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 124.06 Million USD | 16.35% |
| 2024 Q2 | 142.78 Million USD | 15.08% |
| 2023 Q3 | 98.58 Million USD | 217.95% |
| 2023 Q2 | 31 Million USD | -61.07% |
| 2023 Q1 | 79.63 Million USD | 42.19% |
| 2023 Q4 | 106.63 Million USD | 8.17% |
| 2023 FY | 106.63 Million USD | 90.4% |
| 2022 Q4 | 56 Million USD | -5.45% |
| 2022 FY | 56 Million USD | 131.32% |
| 2022 Q2 | 8.65 Million USD | -88.98% |
| 2022 Q3 | 59.23 Million USD | 584.41% |
| 2022 Q1 | 78.56 Million USD | 143.94% |
| 2021 Q4 | -178.8 Million USD | -1629.56% |
| 2021 FY | -178.8 Million USD | -196.25% |
| 2021 Q2 | 126.73 Million USD | -8.15% |
| 2021 Q1 | 137.98 Million USD | -25.72% |
| 2021 Q3 | 11.69 Million USD | -90.78% |
| 2020 FY | 185.77 Million USD | 5.22% |
| 2020 Q2 | 158.44 Million USD | -12.75% |
| 2020 Q3 | 185.71 Million USD | 17.21% |
| 2020 Q4 | 185.77 Million USD | 0.03% |
| 2020 Q1 | 181.6 Million USD | 2.86% |
| 2019 Q3 | 177.28 Million USD | 0.13% |
| 2019 Q2 | 177.05 Million USD | 79.54% |
| 2019 Q1 | 98.61 Million USD | 91.4% |
| 2019 FY | 176.56 Million USD | 242.69% |
| 2019 Q4 | 176.56 Million USD | -0.41% |
| 2018 FY | 51.52 Million USD | 293.81% |
| 2018 Q1 | 63.16 Million USD | 337.61% |
| 2018 Q2 | 71.04 Million USD | 12.48% |
| 2018 Q4 | 51.52 Million USD | -16.37% |
| 2018 Q3 | 61.6 Million USD | -13.28% |
| 2017 Q4 | -26.58 Million USD | -32.29% |
| 2017 FY | -26.58 Million USD | -9.45% |
| 2017 Q3 | -20.09 Million USD | 46.66% |
| 2017 Q2 | -37.67 Million USD | -75.46% |
| 2017 Q1 | -21.47 Million USD | 11.6% |
| 2016 Q3 | -23.02 Million USD | 7.12% |
| 2016 Q4 | -24.28 Million USD | -5.51% |
| 2016 FY | -24.28 Million USD | 45.8% |
| 2016 Q2 | -24.78 Million USD | 36.21% |
| 2016 Q1 | -38.85 Million USD | 13.29% |
| 2015 Q3 | -103.03 Million USD | -281.22% |
| 2015 Q4 | -44.81 Million USD | 56.51% |
| 2015 FY | -44.81 Million USD | -12.16% |
| 2015 Q1 | -5.2 Million USD | 86.97% |
| 2015 Q2 | -27.02 Million USD | -419.15% |
| 2014 Q1 | -26.75 Million USD | -15.69% |
| 2014 FY | -39.95 Million USD | -72.79% |
| 2014 Q4 | -39.95 Million USD | -103.26% |
| 2014 Q3 | -19.65 Million USD | -15.41% |
| 2014 Q2 | -17.03 Million USD | 36.33% |
| 2013 FY | -23.12 Million USD | -204.28% |
| 2013 Q1 | -25.01 Million USD | -229.2% |
| 2013 Q2 | -17.58 Million USD | 29.7% |
| 2013 Q3 | -12.19 Million USD | 30.67% |
| 2013 Q4 | -23.12 Million USD | -89.66% |
| 2012 FY | -7.59 Million USD | 60.28% |
| 2012 Q2 | -20.62 Million USD | -222.47% |
| 2012 Q3 | -10.19 Million USD | 50.56% |
| 2012 Q4 | -7.59 Million USD | 25.49% |
| 2012 Q1 | -6.39 Million USD | 66.57% |
| 2011 FY | -19.13 Million USD | -79.28% |
| 2011 Q4 | -19.13 Million USD | -184.26% |
| 2011 Q2 | -14.74 Million USD | -54.17% |
| 2011 Q1 | -9.56 Million USD | 10.37% |
| 2011 Q3 | -6.73 Million USD | 54.36% |
| 2010 Q1 | -17.23 Million USD | 37.07% |
| 2010 Q4 | -10.67 Million USD | 36.2% |
| 2010 Q3 | -16.72 Million USD | -6.18% |
| 2010 Q2 | -15.75 Million USD | 8.58% |
| 2010 FY | -10.67 Million USD | 61.02% |
| 2009 Q1 | -22.92 Million USD | 18.44% |
| 2009 FY | -27.37 Million USD | 2.58% |
| 2009 Q4 | -27.37 Million USD | -10.69% |
| 2009 Q3 | -24.73 Million USD | -4.11% |
| 2009 Q2 | -23.75 Million USD | -3.66% |
| 2008 FY | -28.1 Million USD | -96.62% |
| 2008 Q4 | -28.1 Million USD | -24.25% |
| 2008 Q3 | -22.61 Million USD | -52.1% |
| 2008 Q2 | -14.87 Million USD | 6.23% |
| 2008 Q1 | -15.85 Million USD | -10.95% |
| 2007 Q3 | -14.64 Million USD | -125.16% |
| 2007 Q1 | -12.97 Million USD | 8.3% |
| 2007 Q2 | -6.5 Million USD | 49.9% |
| 2007 FY | -14.29 Million USD | -0.98% |
| 2007 Q4 | -14.29 Million USD | 2.38% |
| 2006 Q3 | -15.95 Million USD | -58.09% |
| 2006 Q1 | -16.84 Million USD | -93.03% |
| 2006 FY | -14.15 Million USD | -62.22% |
| 2006 Q4 | -14.15 Million USD | 11.27% |
| 2006 Q2 | -10.09 Million USD | 40.09% |
| 2005 Q2 | -5.11 Million USD | 55.13% |
| 2005 FY | -8.72 Million USD | 47.41% |
| 2005 Q4 | -8.72 Million USD | 54.48% |
| 2005 Q1 | -11.4 Million USD | 31.28% |
| 2005 Q3 | -19.16 Million USD | -274.67% |
| 2004 Q4 | -16.59 Million USD | 76.8% |
| 2004 Q3 | -71.51 Million USD | 3.31% |
| 2004 Q1 | -75.01 Million USD | -219.64% |
| 2004 Q2 | -73.95 Million USD | 1.4% |
| 2004 FY | -16.59 Million USD | 29.31% |
| 2003 FY | -23.46 Million USD | -353.84% |
| 2003 Q4 | -23.46 Million USD | 0.0% |
| 2002 FY | -5.17 Million USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 203.578% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 441.593% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 46.162% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -234.436% |
| bluebird bio, Inc. | 108.57 Million USD | 1.783% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 1282.731% |
| Imunon, Inc. | -4.69 Million USD | 2369.181% |
| Editas Medicine, Inc. | -87.11 Million USD | 222.406% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 99.17% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 94.917% |
| Myriad Genetics, Inc. | 88.1 Million USD | -21.039% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 39.856% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 418.057% |
| Verastem, Inc. | -37.27 Million USD | 386.053% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 98.705% |
| Waters Corporation | 1.96 Billion USD | 94.561% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.603% |
| Biogen Inc. | 6.28 Billion USD | 98.304% |
| Nektar Therapeutics | 210.24 Million USD | 49.279% |
| Perrigo Company plc | 3.32 Billion USD | 96.79% |
| Illumina, Inc. | 1.21 Billion USD | 91.216% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -1430.336% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 193.631% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 26.497% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -1383.721% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 71.845% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 1601.901% |
| Evolus, Inc. | 63.7 Million USD | -67.381% |
| Adicet Bio, Inc. | -142 Million USD | 175.091% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 389.738% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 493.487% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 76.753% |
| FibroGen, Inc. | 56.76 Million USD | -87.847% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 90.687% |
| OPKO Health, Inc. | 230.68 Million USD | 53.774% |
| Homology Medicines, Inc. | 18.43 Million USD | -478.375% |
| Geron Corporation | 14.76 Million USD | -622.41% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 93.274% |
| Exelixis, Inc. | -73.05 Million USD | 245.975% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 296.54% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 170.608% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 195.721% |
| Zoetis Inc. | 4.76 Billion USD | 97.761% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 153.365% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 1158.832% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 101.115% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 831.78% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 89.885% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 88.988% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 178.756% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 92.278% |
| Blueprint Medicines Corporation | 702.83 Million USD | 84.828% |
| Insmed Incorporated | 721.62 Million USD | 85.223% |
| TG Therapeutics, Inc. | 17.86 Million USD | -496.994% |
| Incyte Corporation | -3.17 Billion USD | 103.358% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 86.075% |